Abstract: A composition comprising i) oligomeric lactic acid with the following formula (I) wherein n is an integer from 2 to 20, from 2 to 19, or from 2 to 18, and wherein from about 10 to about 20% w/w of the total weight of the oligomeric lactic acid is a trimer, HL3, having n equal to 2, wherein the number average molecular weight Mn of the oligomeric lactic acid is from about 200 to about 500, and ii) a mucoadhesive agent.

Abstract: A composition comprising i) oligomeric lactic acid with the following formula (I) wherein n is an integer from 2 to 20, from 2 to 19, or from 2 to 18, and wherein from about 10 to about 20% w/w of the total weight of the oligomeric lactic acid is a trimer, HL3, having n equal to 2, wherein the number average molecular weight Mn of the oligomeric lactic acid is from about 200 to about 500, and ii) a mucoadhesive agent.

Abstract: The present invention concerns an oral morphine preparation having essentially complete bioavailability and, for the major part of the dissolution, an essentially zero order and essentially pH independent release of morphine for a period of at least 8 hours, preferably at least 12 hours, during which a period less than 100% is dissolved. In the preparation, the morphine, in the form of an easily soluble salt, is present in a combination with a buffering agent in a preparation coated with a diffusion membrane.

Abstract: The invention relates to an oral pharmaceutical multiple units formulation made up of individual cores containing a pharmacologically active substance, the cores being provided with a coating consisting essentially of a polymer that is insoluble in, impermeable to and non-soluble in water and in gastrointestinal fluids, and a water-soluble pore-creating substance, which is randomly distributed in said polymer, whereby said coated cores form units providing an essential zero order diffusion controlled release rate of said active substance. The invention also comprises a method of preparing these formulations.